Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma
Future Oncology · 2023
DOI: 10.2217/fon-2023-0140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Roxanna Seyedin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Anlitiks Inc., Windermere, FL 34786, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Gilead Sciences Kite HQ.
Abstract (Originalsprache)
Aim
To investigate real-world chimeric antigen receptor (CAR) T-cell therapy treatment patterns. Patient & methods: Relapsed/refractory large B-cell lymphoma patients who received CAR T-cell therapy were identified. Patient characteristics, setting of CAR T-cell infusion, incidence of CAR T-cell therapy-associated adverse events and healthcare resource utilization were assessed.
Results
Of 1175 patients, 83% were infused inpatient. Within three days postinfusion, inpatient-infused patients had a significantly higher risk of CAR T-associated adverse events (hazard ratio: 2.67; 95% CI: 2.09-3.42) compared with outpatient-infused patients. By day 30, 67% of outpatient-infused patients were hospitalized at least once.
Conclusion
These findings suggest that physicians were able to select lower-risk patients for outpatient infusion, but postinfusion hospitalizations still occur. This study tracks outcomes in patients with relapsed/refractory large B-cell lymphoma who received chimeric antigen receptor (CAR) T-cell therapy between 2017 and 2020. The authors used the Anlitiks All-Payor Claims (AAPC) database, which includes insurance claims of patients covered through Medicare, Medicaid or commercial insurance plans. AAPC includes over 80% of insured patients in the USA healthcare system. The study describes where patients received CAR T-cell therapy (inpatient/outpatient), rates of adverse events potentially related to CAR T-cell treatment and how much healthcare the patients received. In the 3 days after receiving CAR T-cell therapy, rates of CAR T-associated adverse events were significantly higher in patients who received CAR T-cell therapy in the inpatient setting, compared with outpatients. The findings suggest that lower-risk patients may receive CAR T-cell therapy as outpatients, but that most outpatient-infused patients will still require inpatient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anlitiks Inc., Windermere, FL 34786, USA.
- Kite, a Gilead company, Santa Monica, CA 90404, USA.
- Wade Outcomes Research & Consulting, Salt Lake City, UT 84103, USA.
- Division of Hematology & Oncology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
ORCID-Profile: Roxanna Seyedin, Krithika Rajagopalan
Förderung
- Gilead Sciences Kite HQ
Zitieren
APA
Seyedin, R., Snider, J. T., Rajagopalan, K., Wade, S. W., & Gergis, U. (2023). Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma. Future Oncology. https://doi.org/10.2217/fon-2023-0140
Vancouver
Seyedin R, Snider JT, Rajagopalan K, Wade SW, Gergis U. Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma. Future Oncology. 2023. doi:10.2217/fon-2023-0140
BibTeX
@article{Seyedin2023,
author = {Seyedin, Roxanna and Snider, Julia T and Rajagopalan, Krithika and Wade, Sally W and Gergis, Usama},
title = {Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma},
journal = {Future Oncology},
year = {2023},
doi = {10.2217/fon-2023-0140}
}
EUVIMED